Table 1 PRO assessment and schedule

From: Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab

PRO instrument

Assessment schedule

FACT-FCSI

Baseline, every 2 weeks during treatment, and at the 30-day safety follow-up visit

EUROQOL (EQ-5D) Health Index

Baseline, monthly during treatment, and at the 30-day safety follow-up visit

EUROQOL (EQ-5D) Visual Analog Scale (VAS)

 

EORTC QLQ-C30 Global Health Status/QoL Scale

 
Back to article page